Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933143 | 0.86 | CYP1A2 (0.38) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL29324717 | 0.85 | CYP1A2 (0.42) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL24480556 | 0.81 | ACHE (0.35) | — | |
| SCHEMBL24480647 | 0.79 | CYP1A2 (0.32) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL25815468 | 0.79 | CYP1A2 (0.34) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL24480845 | 0.78 | — | — | |
| SCHEMBL15781119 | 0.77 | CYP1A2 (0.38) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL29324697 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL22564906 | 0.76 | USP2 (0.33) | CYP1A2CYP2D6 | |
| SCHEMBL15112753 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | CYP1A2 2393/4885CYP2D6 755/4885ALOX15 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.